CytomX Therapeutics Q3 2026 Earnings Date & Estimates

CytomX Therapeutics (NASDAQ:CTMX) is a clinical-stage biopharmaceutical company focused on developing antibody-based medicines for cancer and other serious diseases. The company’s technology is designed to keep therapeutic antibodies inactive in healthy tissue and activate them in disease sites, particularly within the tumor microenvironment, with the goal of improving treatment precision and reducing systemic toxicity.

CytomX’s Probody Therapeutics platform uses conditionally activated antibodies and related molecules. Its pipeline has included masked monoclonal antibodies, bispecific T-cell engagers and other immune-modulating therapies directed at targets such as EGFR and CTLA-4. The company advances programs independently and through collaborations with larger pharmaceutical and biotechnology companies.

Founded in 2008 and headquartered in South San Francisco, California, CytomX has developed a global business through research, clinical development and strategic partnerships. Its partnered programs and clinical trials extend the potential reach of its platform beyond the United States, while the company remains primarily focused on advancing oncology medicines toward clinical proof of concept and potential commercialization.